ELTX · Elicio Therapeutics, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-16 | Haqq Christopher |
See Remarks |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests and becomes exercisable as to 50% of the options on July 16, 2027, the first anniversary of the grant date, and as to the remaining 50% of the options on July 16, 2028, the second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Stock Option (Right to Buy)
|
64,643 |
| 2026-07-16 | DeMuth Peter |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests and becomes exercisable as to 50% of the options on July 16, 2027, the first anniversary of the grant date, and as to the remaining 50% of the options on July 16, 2028, the second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Stock Option (Right to Buy)
|
52,832 |
| 2026-07-16 | Connelly Robert |
Director, CEO, President and Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests and becomes exercisable as to 50% of the options on July 16, 2027, the first anniversary of the grant date, and as to the remaining 50% of the options on July 16, 2028, the second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Stock Option (Right to Buy)
|
186,944 |
| 2026-07-16 | Shah Preetam |
See Remarks |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests and becomes exercisable as to 50% of the options on July 16, 2027, the first anniversary of the grant date, and as to the remaining 50% of the options on July 16, 2028, the second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Stock Option (Right to Buy)
|
60,833 |
| 2026-02-02 | Connelly Robert |
Director, CEO, President and Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests and becomes exercisable as to 25% of the options on February 2, 2027, the first anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Stock Option (Right to Buy)
|
147,200 |
| 2026-02-02 | Haqq Christopher |
See Remarks |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs") that will vest as to 25% of the RSUs on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Each RSU represents the right to receive one share of common stock, par value $0.01 per share, of the Issuer. |
Common Stock
|
25,400 |
| 2026-02-02 | Shah Preetam |
See Remarks |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs") that will vest as to 25% of the RSUs on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Each RSU represents the right to receive one share of common stock, par value $0.01 per share, of the Issuer. |
Common Stock
|
24,000 |
| 2026-02-02 | Haqq Christopher |
See Remarks |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests and becomes exercisable as to 25% of the options on February 2, 2027, the first anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Stock Option (Right to Buy)
|
50,900 |
| 2026-02-02 | Shah Preetam |
See Remarks |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests and becomes exercisable as to 25% of the options on February 2, 2027, the first anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Stock Option (Right to Buy)
|
47,900 |
| 2026-02-02 | Connelly Robert |
Director, CEO, President and Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs") that will vest as to 25% of the RSUs on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Each RSU represents the right to receive one share of common stock, par value $0.01 per share, of the Issuer. |
Common Stock
|
73,600 |
| 2026-02-02 | DeMuth Peter |
Chief Scientific Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs") that will vest as to 25% of the RSUs on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Each RSU represents the right to receive one share of common stock, par value $0.01 per share, of the Issuer. |
Common Stock
|
20,800 |
| 2026-02-02 | DeMuth Peter |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests and becomes exercisable as to 25% of the options on February 2, 2027, the first anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Stock Option (Right to Buy)
|
41,600 |
| 2025-12-09 | DeMuth Peter |
Chief Scientific Officer |
Convert↑
|
Common Stock
|
362 |
| 2025-12-09 | DeMuth Peter |
Chief Scientific Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vested and became exercisable as to (i) 25% of the options on the first anniversary of the grant date or December 10, 2016, and (ii) with the remaining shares vesting at a rate of 2.0833% at the end of each month thereafter. |
Stock Option (Right to Buy)
|
362 |
| 2025-06-03 | Chudnovsky Yekaterina |
Director, 10% Owner |
Award↑
Filing footnotes — Warrant (right to buy) (Indirect)
Yekaterina (Katie) Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC. |
Warrant (right to buy)
(I)
|
103,225 |
| 2025-05-19 | RUFFOLO ROBERT R |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
7,900 |
| 2025-05-19 | ADAMS JULIAN |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
7,900 |
| 2025-05-19 | Venkatesan Jay |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
7,900 |
| 2025-05-19 | Ashe Carol Gail |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
7,900 |
| 2025-05-19 | WILSON KAREN J |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
7,900 |
| 2025-05-19 | Chudnovsky Yekaterina |
Director, 10% Owner |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
7,900 |
| 2025-05-19 | Nissenson Allen |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
7,900 |
| 2025-04-15 | Shah Preetam |
See Remarks |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests and becomes exercisable as to 25% of the options on March 24, 2025, the first anniversary of the Reporting Person's start date, with the remaining options vesting in equal monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Stock Option (Right to Buy)
|
191,624 |
| 2025-03-24 | Shah Preetam |
See Remarks |
Other↑
|
No Securities Owned
|
0 |
| 2025-03-05 | Chudnovsky Yekaterina |
Director, 10% Owner |
Other↓
Filing footnotes — Convertible Note (convertible into Common Stock) (Indirect)
The Convertible Note had a stated maturity date of February 15, 2026. The Convertible Note, including any accrued but unpaid interest, was converted into shares of Common Stock on March 5, 2025 at a conversion price of $5.81 per share. Yekaterina (Katie) Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC. |
Convertible Note (convertible into Common Stock)
(I)
|
3,442,341 |
| 2025-03-05 | Chudnovsky Yekaterina |
Director, 10% Owner |
Other↑
Filing footnotes — Common Stock (Indirect)
Yekaterina (Katie) Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC. |
Common Stock
(I)
|
3,500,573 |
| 2025-02-03 | Haqq Christopher |
See Remarks |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests and becomes exercisable as to 25% of the options on the first anniversary of the grant date (February 3, 2026), with the remaining options vesting in equal monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Stock Option (Right to Buy)
|
44,000 |
| 2025-02-03 | DeMuth Peter |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests and becomes exercisable as to 25% of the options on the first anniversary of the grant date (February 3, 2026), with the remaining options vesting in equal monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Stock Option (Right to Buy)
|
44,400 |
| 2025-02-03 | Connelly Robert |
Director, CEO, President and Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests and becomes exercisable as to 25% of the options on the first anniversary of the grant date (February 3, 2026), with the remaining options vesting in equal monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Stock Option (Right to Buy)
|
121,600 |
| 2024-12-16 | DeMuth Peter |
Chief Scientific Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vested and became exercisable as to (i) 25% of the options on the first anniversary of the grant date or December 18, 2015, and (ii) with the remaining shares vesting at a rate of 2.0833% at the end of each month thereafter. |
Stock Option (Right to Buy)
|
381 |
| 2024-12-16 | DeMuth Peter |
Chief Scientific Officer |
Convert↑
|
Common Stock
|
381 |
| 2024-11-26 | Venkatesan Jay |
Director |
Exercise↑
Filing footnotes — Common Stock (Direct)
On November 26, 2024, the Reporting Person exercised a pre-funded warrant to purchase an aggregate of 50,000 shares of the Issuer's common stock. |
Common Stock
|
50,000 |
| 2024-11-26 | Venkatesan Jay |
Director |
Exercise↓
Filing footnotes — Warrant to Purchase Common Stock (Direct)
N/A |
Warrant to Purchase Common Stock
|
50,000 |
| 2024-11-21 | Venkatesan Jay |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
4,100 |
| 2024-11-21 | Chudnovsky Yekaterina |
Director, 10% Owner |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
4,100 |
| 2024-11-21 | Nissenson Allen |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
4,100 |
| 2024-11-21 | Ashe Carol Gail |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
4,100 |
| 2024-11-21 | WILSON KAREN J |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
4,100 |
| 2024-11-21 | ADAMS JULIAN |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
4,100 |
| 2024-11-21 | RUFFOLO ROBERT R |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
4,100 |
| 2024-09-30 | Haqq Christopher |
See Remarks |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Fifty percent (50%) of the stock options vest on September 30, 2025, the one-year anniversary of the grant date, with the remaining fifty percent (50%) of the stock options to vest on September 30, 2026, the two-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. |
Stock Option (Right to Buy)
|
28,200 |
| 2024-09-30 | DeMuth Peter |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Fifty percent (50%) of the stock options vest on September 30, 2025, the one-year anniversary of the grant date, with the remaining fifty percent (50%) of the stock options to vest on September 30, 2026, the two-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Stock Option (Right to Buy)
|
29,800 |
| 2024-09-30 | Connelly Robert |
Director, CEO, President and Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Fifty percent (50%) of the stock options vest on September 30, 2025, the one-year anniversary of the grant date, with the remaining fifty percent (50%) of the stock options to vest on September 30, 2026, the two-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Stock Option (Right to Buy)
|
91,600 |
| 2024-08-12 | Chudnovsky Yekaterina |
Director, 10% Owner |
Buy↑
Filing footnotes — Convertible Note (convertible into Common Stock) (Indirect)
On August 12, 2024, GKCC, LLC (the "Purchaser") purchased from the Issuer a convertible note with an aggregate principal amount of $20,000,000 (the "Convertible Note"). The Convertible Note is convertible into shares of common stock of the Issuer at a conversion price of $5.81 per share, subject to adjustment in certain circumstances. Therefore, the Convertible Note is initially convertible into approximately 3,442,341 shares of common stock of the Issuer. The Convertible Note will mature on February 15, 2026, unless earlier converted in accordance with the terms of the Convertible Note. Interest on the Convertible Note is payable in cash and will accrue and be payable quarterly on the principal amount equal to 3% per annum. Yekaterina (Katie) Chudnovsky is the sole member and manager of the Purchaser and may be deemed to beneficially own the shares held by the Purchaser. |
Convertible Note (convertible into Common Stock)
(I)
|
3,442,341 |
| 2024-06-28 | Venkatesan Jay |
Director |
Buy↑
Filing footnotes — Pre-Funded Warrants (Direct)
Each Pre-Funded Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%. The Pre-Funded Warrants do not have an expiration date. On July 2, 2024, the Reporting Person mistakenly filed a Form 4 reporting the acquisition of an additional 150,000 Common Warrants and 150,000 Pre-Funded Warrants. The Reporting Person is not the beneficial owner of such Common Warrants or Pre-Funded Warrants. As of January 2, 2025, the Reporting Person owned only the Common Warrants and Pre-Funded Warrants reported herein. |
Pre-Funded Warrants
|
50,000 |
| 2024-06-28 | Chudnovsky Yekaterina |
Director, 10% Owner |
Buy↑
Filing footnotes — Pre-Funded Warrants (Direct)
Each Pre-Funded Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 19.99%. The Pre-Funded Warrants do not have an expiration date. |
Pre-Funded Warrants
|
1,600,000 |
| 2024-06-28 | Venkatesan Jay |
Director |
Buy↑
Filing footnotes — Common Warrants (Direct)
Each Common Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $5.00 per share, subject to adjustments as provided under the terms of the Common Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%. The Common Warrants expire on July 1, 2029. On July 2, 2024, the Reporting Person mistakenly filed a Form 4 reporting the acquisition of an additional 150,000 Common Warrants and 150,000 Pre-Funded Warrants. The Reporting Person is not the beneficial owner of such Common Warrants or Pre-Funded Warrants. As of January 2, 2025, the Reporting Person owned only the Common Warrants and Pre-Funded Warrants reported herein. |
Common Warrants
|
50,000 |
| 2024-06-28 | Chudnovsky Yekaterina |
Director, 10% Owner |
Buy↑
Filing footnotes — Common Warrants (Direct)
Each Common Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $5.00 per share, subject to adjustments as provided under the terms of the Common Warrant, subject to a post-exercise beneficial ownership limitation of 19.99%. The Common Warrants expire on July 1, 2029. |
Common Warrants
|
1,600,000 |
| 2024-03-19 | Chudnovsky Yekaterina |
Director, 10% Owner |
Buy↑
Filing footnotes — Pre-Funded Common Stock Purchase Warrant (Indirect)
Each Pre-Funded Warrant will be exercisable by GKCC, LLC at any time on or after March 19, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 19.99%, unless stockholder approval is obtained. The Pre-Funded Warrants do not have an expiration date. Yekaterina (Katie) Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC. |
Pre-Funded Common Stock Purchase Warrant
(I)
|
1,032,702 |
| 2024-02-01 | Piekos Brian |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Twenty five percent (25%) of the stock options vest on February 1, 2025, the one-year anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Stock Option (right to buy)
|
43,225 |